GT Biopharma is trading 5.99% down at $6.75 after opening-session selling on September 22, 2026.
- No new company-specific announcement dated September 22 was identified.
- Available coverage does not explicitly connect a catalyst to the decline.
- A September 15 financing disclosed convertible preferred stock and warrants with a $6.10 conversion and exercise price, predating today’s move.